It has been hypothesized that a biphasic type I IFN response consisting of an early protective response and a subsequent immunopathogenic response may operate during COVID-19, and randomized clinical trials are currently underway to evaluate the efficacy of either IFN-β or JAK inhibitors, which inhibit type I IFN signaling, in COVID-19. The gene discussed is IFNB1; the disease is COVID-19.